NCT06654206Not yet recruitingEarly phase 1
Effects of a Strength Physical Exercise Program in Chronic Lymphocytic Leukemia Patients
Effects of a Strength Physical Exercise Program in Chronic Lymphocytic Leukemia Patients on Quality of Life, Mental Health, and Frailty.
Source: ClinicalTrials.gov · Last updated 19 Feb 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Chronic lymphocytic leukemia (CLL) is a hematological neoplasm that primarily affects older individuals and is the most common type of leukemia in adults in Western countries. CLL mainly affects older adults, with an average age at diagnosis of around 70 years, and there is a slightly higher risk in men compared to women. It is characterized by the proliferation of clonal B lymphocytes in peripheral blood, bone marrow, and lymphoid organs. Although CLL has a relatively slow progression in many cases, patients may experience chronic fatigue, muscle weakness, functional impairment, and psychological disorders, such as anxiety and depression, which significantly affect their quality of life. In this context, it has been shown that physical exercise, especially strength training, can considerably improve physical and psychological conditions in oncology populations, such as those with breast cancer and colorectal cancer, as well as in older adults, where the benefits of resistance training are widely recognized. These benefits include increased muscle strength, reduced fatigue, improved functional abilities, psychological well-being, and overall quality of life. Furthermore, there is evidence that exercise can reduce systemic inflammatory markers, such as C-reactive protein (CRP), and improve lipid profiles by lowering total cholesterol and triglycerides, which is crucial for cancer patients at risk of cardiovascular diseases.
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Early phase 1
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- First submitted
- 21 Oct 2024
- Start date
- 10 Mar 2025
- Primary completion date
- 31 Dec 2025
- Lead sponsor
- University of Salamanca
- NCT number
- NCT06654206
What you commit to
- Study type: Interventional · Early phase 1
- Planned participants: 40
- From 10 Mar 2025 to the primary completion date, 31 Dec 2025
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- The presence of any medical contraindications to physical exercise, such as severe musculoskeletal disorders, serious cardiovascular diseases, bone metastases, or other conditions as determined by a healthcare professional.
Other
- Participants unable to complete the initial evaluation tests or who have difficulty performing basic exercises.
- Other circumstances, as determined by the researchers, that may interfere with the study's objectives or development.
- Participants will be discontinued if they meet any of the following:
- Negative developments or progression of the tumor process.
- Severe adverse events related to exercise.
- Voluntary withdrawal from the intervention.
- New medical contraindications that prevent safe participation.
- Non-adherence to the intervention protocol that compromises study integrity.
Who the study is looking for
- Participants diagnosed with CLL or Small Lymphocytic Lymphoma (SLL) undergoing active treatment.
- Participants who have not engaged in regular physical activity in the past 8 weeks.
- Performance Status (ECOG) 0-1.
- Signed informed consent.
Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.